CDK4 and cancer: We have shown that increased activation of the PI3K/AKT/mTOR signalling axis in samples collected from MBC patients that develop disease progression when treated with a CDK4/6 inhibitor in combination with ET extends beyond cancer cells into the surrounding stroma/immune compartment [5].